JP6368777B2 - ピリミジン化合物およびガンマセクレターゼモジュレーターとしてのその使用 - Google Patents

ピリミジン化合物およびガンマセクレターゼモジュレーターとしてのその使用 Download PDF

Info

Publication number
JP6368777B2
JP6368777B2 JP2016517275A JP2016517275A JP6368777B2 JP 6368777 B2 JP6368777 B2 JP 6368777B2 JP 2016517275 A JP2016517275 A JP 2016517275A JP 2016517275 A JP2016517275 A JP 2016517275A JP 6368777 B2 JP6368777 B2 JP 6368777B2
Authority
JP
Japan
Prior art keywords
methyl
methoxy
imidazol
trifluoroethoxy
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016517275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520637A (ja
JP2016520637A5 (enExample
Inventor
エフゲニ・ベシドスキー
ウルリーカ・イングヴェ
キム・ポールセン
クリスティアン・リンデ
イストバン・マッサリ
ヨーナス・マルムボリ
アレクサンデル・パッチキーネ
ペール・アルヴィドソン
Original Assignee
アクチュラム・ライフ・サイエンス・アクチエボラーグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクチュラム・ライフ・サイエンス・アクチエボラーグ filed Critical アクチュラム・ライフ・サイエンス・アクチエボラーグ
Publication of JP2016520637A publication Critical patent/JP2016520637A/ja
Publication of JP2016520637A5 publication Critical patent/JP2016520637A5/ja
Application granted granted Critical
Publication of JP6368777B2 publication Critical patent/JP6368777B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016517275A 2013-06-04 2014-06-03 ピリミジン化合物およびガンマセクレターゼモジュレーターとしてのその使用 Expired - Fee Related JP6368777B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1350685 2013-06-04
SE1350685-2 2013-06-04
PCT/EP2014/061503 WO2014195323A1 (en) 2013-06-04 2014-06-03 Pyrimidine compounds and their use as gamma secretase modulators

Publications (3)

Publication Number Publication Date
JP2016520637A JP2016520637A (ja) 2016-07-14
JP2016520637A5 JP2016520637A5 (enExample) 2017-06-01
JP6368777B2 true JP6368777B2 (ja) 2018-08-01

Family

ID=50877325

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016517275A Expired - Fee Related JP6368777B2 (ja) 2013-06-04 2014-06-03 ピリミジン化合物およびガンマセクレターゼモジュレーターとしてのその使用

Country Status (9)

Country Link
US (1) US9439904B2 (enExample)
EP (1) EP3004079B1 (enExample)
JP (1) JP6368777B2 (enExample)
CN (1) CN105263923B (enExample)
DK (1) DK3004079T3 (enExample)
ES (1) ES2665421T3 (enExample)
NO (1) NO3004079T3 (enExample)
PL (1) PL3004079T3 (enExample)
WO (1) WO2014195323A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6975514B2 (ja) * 2016-07-08 2021-12-01 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 縮合ピリミジン誘導体
CN108191776A (zh) * 2018-01-22 2018-06-22 无锡富泽药业有限公司 一种尿嘧啶的绿色生产工艺
WO2020247707A1 (en) * 2019-06-05 2020-12-10 Chunyu Wang SYSTEMS AND METHOD FOR INHIBITING γ-SECRETASE PRODUCTION OF AMYLOID-β PEPTIDES
US12297244B2 (en) 2019-06-05 2025-05-13 Rensselaer Polytechnic Institute Systems and methods for inhibiting γ-secretase production of amyloid-β peptides
CN110372603A (zh) * 2019-06-24 2019-10-25 南京普锐达医药科技有限公司 一种2-氯-5-氟-6-乙基嘧啶的合成方法
CN113149977A (zh) 2020-01-22 2021-07-23 苏州爱科百发生物医药技术有限公司 一类呼吸道合胞病毒抑制剂的合成与用途
MX2023011027A (es) 2021-03-23 2023-09-27 Halia Therapeutics Inc Derivados de pirimidina utiles como inhibidores de la proteina cinasa de repeticion 2 rica en leucina (lrrk2).

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002528499A (ja) * 1998-10-29 2002-09-03 ブリストル−マイヤーズ スクイブ カンパニー Ｉｍｐｄｈ酵素のインヒビターであるアミノ核誘導化合物
ITMI20030312A1 (it) 2003-02-21 2004-08-22 Chiesi Farma Spa Derivati di acidi 2-fenil-2-alchil-acetici per il trattamento della malattia di alzheimer.
ATE464048T1 (de) 2003-08-07 2010-04-15 Merck Sharp & Dohme Behandlung von alzheimer-krankheit und verwandten zuständen
JP2007513128A (ja) 2003-12-03 2007-05-24 メルク　エンド　カムパニー　インコーポレーテッド アルツハイマー病および関連状態の治療に有用な１−アルキル−３−チオ置換インドール−２−アルキン酸
US7667041B2 (en) 2004-05-26 2010-02-23 Eisai R&D Management Co., Ltd. Cinnamide compound
MY167260A (en) * 2005-11-01 2018-08-14 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
CA2649996A1 (en) 2006-04-26 2007-11-08 Merck Sharp & Dohme Limited Piperidines and related compounds for treatment of alzheimer's disease
AU2007252643A1 (en) 2006-05-19 2007-11-29 Eisai R & D Management Co., Ltd. Urea type cinnamide derivative
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
WO2008097538A1 (en) 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
CA2676920A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperidine derivatives
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
WO2008156580A1 (en) 2007-06-13 2008-12-24 Merck & Co., Inc. Triazole derivatives for treating alzheimer's disease and related conditions
US20110009392A1 (en) 2007-08-06 2011-01-13 Schering Corporation Gamma secretase modulators
ATE535515T1 (de) 2008-01-11 2011-12-15 Hoffmann La Roche Modulatoren für amyloid beta
RU2010137300A (ru) 2008-02-22 2012-03-27 Ф. Хоффманн-Ля Рош Аг (Ch) Модуляторы бета-амилоида
CN102177151A (zh) * 2008-10-09 2011-09-07 弗·哈夫曼-拉罗切有限公司 β-淀粉样蛋白的调节剂
CN102272133A (zh) 2008-11-06 2011-12-07 阿斯利康(瑞典)有限公司 淀粉样β的调节剂
MX2011004954A (es) 2008-11-10 2011-05-30 Hoffmann La Roche Moduladores heterociclicos de gamma-secretasa.
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
UY32622A (es) 2009-05-12 2010-12-31 Astrazeneca Ab Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta)
EA021047B1 (ru) 2009-07-15 2015-03-31 Янссен Фармасьютикалз, Инк. Замещенные производные триазола и имидазола в качестве модуляторов гамма-секретазы
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
MX2012008260A (es) 2010-01-15 2012-08-17 Janssen Pharmaceuticals Inc Novedosos derivados de triazol sustituidos como moduladores de la gamma secretasa.
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
TW201206946A (en) 2010-07-15 2012-02-16 Bristol Myers Squibb Co Compounds for the reduction of beta-amyloid production

Also Published As

Publication number Publication date
NO3004079T3 (enExample) 2018-06-16
ES2665421T3 (es) 2018-04-25
US20160129002A1 (en) 2016-05-12
WO2014195323A1 (en) 2014-12-11
JP2016520637A (ja) 2016-07-14
EP3004079B1 (en) 2018-01-17
EP3004079A1 (en) 2016-04-13
CN105263923A (zh) 2016-01-20
CN105263923B (zh) 2017-06-23
US9439904B2 (en) 2016-09-13
DK3004079T3 (en) 2018-04-16
PL3004079T3 (pl) 2018-07-31

Similar Documents

Publication Publication Date Title
JP6368777B2 (ja) ピリミジン化合物およびガンマセクレターゼモジュレーターとしてのその使用
US20230107277A1 (en) Substituted pyridazine compound
US10568884B2 (en) Compounds and compositions as protein kinase inhibitors
JP4778657B2 (ja) ＧＳＫ３．β阻害剤としての２−アミノ−３−（アルキル）−ピリミドン誘導体
JP6741697B2 (ja) 新規なヒドロキシエステル誘導体、その調製方法及びそれを含有する医薬組成物
JP5581318B2 (ja) 神経変性疾患治療用のｇｓｋ３−ベータ阻害剤としての４−（ピリジン−４−イル）−１ｈ−（１，３，５）トリアジン−２−オン誘導体
ES2323576T3 (es) Derivados de 4-pirimidona 3-sustituida.
JP4572195B2 (ja) ８−置換−６，７，８，９−テトラヒドロピリミド［１，２−ａ］ピリミジン−４−オン誘導体
KR20040048920A (ko) 글리코겐 신타아제 키나제 3-베타 저해제(ｇｓｋ저해제)로서의 헤테로아릴 아민
JP2005510472A (ja) ３−置換−４−ピリミドン誘導体
JP6368776B2 (ja) トリアゾール化合物およびガンマセクレターゼモジュレーターとしてのその使用
US12234218B2 (en) Heterocyclic compounds as modulators of mGluR7
US12404253B2 (en) 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1
JP5124471B2 (ja) 置換二環式ピリミドン誘導体
US20120122843A1 (en) Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases
TW202132305A (zh) 腺苷受體拮抗劑化合物
JP4484524B2 (ja) １−［アルキル］、１−［（ヘテロアリール）アルキル］および１−［（アリール）アルキル］−７−（ピリミジン−４−イル）−イミダゾ［１，２−ａ］ピリミジン−５（１Ｈ）−オン誘導体
AU2014340249A1 (en) Substituted pyrimidine compounds and their use as SYK inhibitors
JP6396438B2 (ja) トリアゾール化合物およびガンマセクレターゼモジュレーターとしてのその使用
KR102409595B1 (ko) 단백질 카이네이즈 csf-1r 억제제로서의 신규 퓨리논 유도체
JP2005154434A (ja) ２−アミノキナゾリン誘導体
KR101121662B1 (ko) 도파민 ｄ3, ｄ4 수용체 길항제인 신규 3-(메톡시메틸)피라졸 유도체, 이의 제조방법 및 이를 포함하는 약학적 조성물
HK1138274A1 (en) Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160218

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20160218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170414

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180525

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180703

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180709

R150 Certificate of patent or registration of utility model

Ref document number: 6368777

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees